BR0316346A - Vacina para vìrus do nilo ocidental - Google Patents

Vacina para vìrus do nilo ocidental

Info

Publication number
BR0316346A
BR0316346A BR0316346-6A BR0316346A BR0316346A BR 0316346 A BR0316346 A BR 0316346A BR 0316346 A BR0316346 A BR 0316346A BR 0316346 A BR0316346 A BR 0316346A
Authority
BR
Brazil
Prior art keywords
west nile
nile virus
virus vaccine
vaccines
methods
Prior art date
Application number
BR0316346-6A
Other languages
English (en)
Other versions
BRPI0316346B1 (pt
Inventor
Juan Arroyo
John Avram Catalan
Charles M Miller
Thomas P Monath
Original Assignee
Acambis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acambis Inc filed Critical Acambis Inc
Publication of BR0316346A publication Critical patent/BR0316346A/pt
Publication of BRPI0316346B1 publication Critical patent/BRPI0316346B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"VACINA PARA VìRUS DO NILO OCIDENTAL". A invenção refere-se a vacinas de flavivírus quimérico contra vírus do Nilo Ocidental e métodos de uso dessas vacinas para prevenir ou tratar infecção pelo vírus do Nilo Ocidental.
BRPI0316346A 2002-11-15 2003-11-13 molécula de ácido nucleico, flavivírus quimérico, uso do referido flavivírus e método de fabricação de vacina de flavivírus quimérico contra vírus do nilo ocidental BRPI0316346B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42659202P 2002-11-15 2002-11-15
PCT/US2003/036623 WO2004045529A2 (en) 2002-11-15 2003-11-13 West nile virus vaccine

Publications (2)

Publication Number Publication Date
BR0316346A true BR0316346A (pt) 2005-09-27
BRPI0316346B1 BRPI0316346B1 (pt) 2016-05-31

Family

ID=32326380

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0316346A BRPI0316346B1 (pt) 2002-11-15 2003-11-13 molécula de ácido nucleico, flavivírus quimérico, uso do referido flavivírus e método de fabricação de vacina de flavivírus quimérico contra vírus do nilo ocidental

Country Status (16)

Country Link
US (2) US7507415B2 (pt)
EP (1) EP1575979B1 (pt)
JP (1) JP4683926B2 (pt)
KR (1) KR101150584B1 (pt)
AT (1) ATE452900T1 (pt)
AU (1) AU2003290985B2 (pt)
BR (1) BRPI0316346B1 (pt)
CA (1) CA2505942C (pt)
DE (1) DE60330708D1 (pt)
ES (1) ES2337893T3 (pt)
HK (1) HK1083192A1 (pt)
IL (2) IL168584A (pt)
MX (1) MXPA05005140A (pt)
RU (1) RU2376374C2 (pt)
WO (1) WO2004045529A2 (pt)
ZA (1) ZA200503871B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
CN1551782A (zh) * 2001-06-01 2004-12-01 ��������ķ������ 嵌合黄病毒载体
EP1471873A4 (en) 2002-01-15 2005-03-16 Acambis Inc VACCINES AGAINST FLAVIVIRUS
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
US7785799B2 (en) * 2002-08-16 2010-08-31 The Board Of Regents Of The University Of Texas System Compositions and methods related to flavivirus envelope protein domain III antigens
DE60330708D1 (de) 2002-11-15 2010-02-04 Sanofi Pasteur Biologics Co Impfstoff gegen das west-nile-virus
US7482017B2 (en) 2004-09-09 2009-01-27 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
EA015907B1 (ru) * 2004-10-20 2011-12-30 Санофи Пастер Байолоджикс Ко. Рекомбинантный флавивирус и его применение
AU2005320001B2 (en) 2004-12-24 2011-05-19 The Research Foundation For Microbial Diseases Of Osaka University Attenuated chimeric flavivirus bearing attenuated Japanese encephalitis virus gene as backbone
BRPI0609949A2 (pt) 2005-04-24 2010-05-11 Acambis Inc flavivìrus recombinante, seu uso na preparação de vacina, composição farmacêutica compreendendo o mesmo, molécula de ácido nucléico e método para atenuar candidato a vacina de flavivìrus
AU2013204985B2 (en) * 2005-04-24 2016-01-28 Sanofi Pasteur Biologics, Llc Recombinant flavivirus vaccines
US8017754B2 (en) * 2005-07-22 2011-09-13 Research Development Foundation Attenuated virus strains and uses thereof
RU2541784C2 (ru) 2006-11-07 2015-02-20 Санофи Пастер Байолоджикс Ко. Лиофилизированная композиция для индукции иммунного ответа на флавивирус, композиция и способ для ее получения
WO2008143713A2 (en) * 2006-12-22 2008-11-27 Dow Agrosciences Llc Plant-made west nile virus (wnv) vaccines, vectors and plant codon optimized sequences
EP2589392B1 (en) 2008-03-05 2016-11-30 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
SG193821A1 (en) * 2008-08-29 2013-10-30 Boehringer Ingelheim Vetmed West nile virus vaccine
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
US8999675B2 (en) * 2009-08-31 2015-04-07 Gen-Probe Incorporated Dengue virus assay
US10081795B2 (en) * 2010-03-24 2018-09-25 Research Development Foundation Flavivirus host range mutations and uses thereof
WO2012003320A2 (en) 2010-07-01 2012-01-05 Research Development Foundation Flavivirus host-range mutations and uses thereof
BR112013023354B1 (pt) 2011-03-14 2022-02-15 Boehringer Ingelheim Animal Health Usa Inc Composição imunogênica compreendendo cepas de vírus da rinite equina a (erav) e seu método de produção
WO2013138670A1 (en) * 2012-03-15 2013-09-19 Icahn School Of Medicine At Mount Sinai Yellow fever virus ns5 mutants as flavivirus vaccine candidates
US9267114B2 (en) * 2012-11-07 2016-02-23 Southern Research Institute Flavivirus envelope protein mutations affecting virion disassembly

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
ES2153223T3 (es) 1991-09-19 2001-02-16 Us Health Flavivirus quimericos y/o flavivirus de crecimiento restringido.
US6136561A (en) * 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
DE69841690D1 (de) 1997-02-28 2010-07-08 Acambis Inc Chimäre Impfstoffe gegen Flaviviren
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
BRPI9701774B8 (pt) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6416763B1 (en) * 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
WO2001039802A1 (en) 1999-12-01 2001-06-07 Oravax, Inc. Chimeric flavivirus vaccines
GB2372991B (en) 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
CN1551782A (zh) 2001-06-01 2004-12-01 ��������ķ������ 嵌合黄病毒载体
US6682883B1 (en) * 2001-07-19 2004-01-27 Acambis, Inc. Diagnosis of flavivirus infection
RU2313367C2 (ru) 2001-10-19 2007-12-27 Экэмбис, Инк. Способы профилактики и лечения инфекции, вызываемой флавивирусами у животных
DE20120256U1 (de) * 2001-12-14 2002-03-07 Haefele Gmbh & Co Beschlag
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
EP1471873A4 (en) 2002-01-15 2005-03-16 Acambis Inc VACCINES AGAINST FLAVIVIRUS
US20040259224A1 (en) 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
DE60330708D1 (de) * 2002-11-15 2010-02-04 Sanofi Pasteur Biologics Co Impfstoff gegen das west-nile-virus
US7189403B2 (en) 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
WO2005040390A1 (fr) 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. Vaccin recombine utilisant le virus de la fievre jaune comme vecteur
WO2005049815A1 (en) 2003-11-21 2005-06-02 K.U.Leuven Research & Development Flavivirus replication
EA015907B1 (ru) 2004-10-20 2011-12-30 Санофи Пастер Байолоджикс Ко. Рекомбинантный флавивирус и его применение
BRPI0609949A2 (pt) 2005-04-24 2010-05-11 Acambis Inc flavivìrus recombinante, seu uso na preparação de vacina, composição farmacêutica compreendendo o mesmo, molécula de ácido nucléico e método para atenuar candidato a vacina de flavivìrus
BRPI0504945B8 (pt) 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.

Also Published As

Publication number Publication date
RU2376374C2 (ru) 2009-12-20
WO2004045529A3 (en) 2004-08-26
US20050053624A1 (en) 2005-03-10
ZA200503871B (en) 2006-08-30
EP1575979B1 (en) 2009-12-23
AU2003290985A1 (en) 2004-06-15
JP2006506092A (ja) 2006-02-23
ATE452900T1 (de) 2010-01-15
US7507415B2 (en) 2009-03-24
RU2005118419A (ru) 2006-01-20
BRPI0316346B1 (pt) 2016-05-31
MXPA05005140A (es) 2005-08-19
CA2505942A1 (en) 2004-06-03
KR20050072143A (ko) 2005-07-08
HK1083192A1 (en) 2006-06-30
EP1575979A4 (en) 2006-06-21
US20100086564A1 (en) 2010-04-08
IL202978A0 (en) 2011-08-01
US8088391B2 (en) 2012-01-03
EP1575979A2 (en) 2005-09-21
KR101150584B1 (ko) 2012-06-27
WO2004045529A2 (en) 2004-06-03
AU2003290985B2 (en) 2010-04-01
CA2505942C (en) 2012-03-13
IL202978A (en) 2013-11-28
ES2337893T3 (es) 2010-04-30
IL168584A (en) 2010-12-30
DE60330708D1 (de) 2010-02-04
JP4683926B2 (ja) 2011-05-18
US20070275015A9 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
BR0316346A (pt) Vacina para vìrus do nilo ocidental
MX2022011671A (es) Vacunas contra el coronavirus y metodos de uso.
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
MY148075A (en) Vaccines against japanese encephalitis virus and west nile virus
WO2003101397A3 (en) Tetravalent dengue vaccines
DK1773999T3 (da) Vaccine til forebyggelse og behandling af HIV-infektion
ATE426412T1 (de) Adjuvante influenza-vakzine
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
ATE511398T1 (de) Inaktiviertes poliovirus mischimpfstoff
NO20061911L (no) Immunogene sammensetninger
EA201070794A1 (ru) Рекомбинантные антигены rsv
NO20070551L (no) Vaksinesammensetninger og fremgangsmater for behandling av koronavirus infeksjon.
DK1487485T3 (da) Imidazoquinolinadjuvanser til DNA-vacciner
WO2003103571A3 (en) VACCINES AGAINST FLAVIVIRUSES
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
EA201170493A1 (ru) Микроорганизмы и вакцины, зависимые от репликации неприродных аминокислот
CY2016018I2 (el) Εμβολιο κατα του ιου του δυτικου νειλου
GB0109297D0 (en) Vaccine
UY27798A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatits c y composiciones y tratamientos que los usan.
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
DK1949913T3 (da) Immunstimulatorisk kombination til profylakserne og behandlingen af hepatitis C
EP1575601A4 (en) RECOMBINANT VACCINE VIRUSES EXPRESSING IL-15 AND METHODS OF USING THE SAME VIRUSES
BRPI0516314A (pt) uso de hiv inteiro e método de tratamento de um indivìduo cronicamente infectado com hiv

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07H 21/04 , A61K 39/00 , A61K 39/12 , C12P 21/00

Ipc: A61K 39/12 (2006.01), C12N 15/40 (2006.01), C12N 7

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 31/05/2016, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved
B25D Requested change of name of applicant approved
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2493 DE 16-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.